Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction.

ESC Heart Failure
Luka CavkaMitja Lainscak

Abstract

The number of patients receiving sodium-glucose cotransporter 2 inhibitors (SGLT2is), especially those with heart failure, is increasing worldwide. SGLT2is control glycaemia by triggering glycosuria with simultaneous facilitation of a more ketogenic metabolic profile. Patients therefore are more prone to develop euglycaemic diabetic ketoacidosis (euDKA), an entity largely unknown beyond diabetes care professionals. We present a heart failure with preserved ejection fraction (HFpEF) patient with known Type 2 diabetes. He was treated with dapagliflozin and presented acutely with dyspnoea, hyperglycaemia, and ketoacidosis. After standard treatment for diabetic ketoacidosis, hyperglycaemia was corrected, while metabolic ketoacidosis persisted, and thus, euDKA was suspected. With adequate therapy, the patient recovered completely and was discharged without any sequelae. To the best of our knowledge, our case is the first to describe SGLT2i-induced euDKA in HFpEF patients. Regarding no previous reports of euDKA in heart failure with reduced ejection fraction, our report is highly relevant for ongoing SGLT2i trials in HFpEF and clinical practice in general.

References

Jun 9, 1973·British Medical Journal·J F MunroL J Duncan
Jul 1, 2009·Diabetes Care·Abbas E KitabchiJoseph N Fisher
Dec 23, 2014·European Journal of Clinical Pharmacology·Tina RoblekMitja Lainscak
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Apr 5, 2016·Journal of Diabetes Investigation·Wataru Ogawa, Kazuhiko Sakaguchi
May 4, 2017·European Journal of Heart Failure·Ovidiu ChioncelUNKNOWN ESC Heart Failure Long-Term Registry Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Mar 27, 2019·European Journal of Internal Medicine·Leonid BarskiAlan Jotkowitz
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
May 20, 2020·Current Diabetes Reports·Benedetta Maria BonoraGian Paolo Fadini
Jul 16, 2020·Nature Reviews. Cardiology·Martin R Cowie, Miles Fisher
Aug 1, 2020·Kidney Medicine·Katherine M Wang, Robert T Isom
Aug 17, 2020·The Journal of Biological Chemistry·Rachel J Perry, Gerald I Shulman
Aug 28, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·David M Williams, Marc Evans
Nov 18, 2020·The New England Journal of Medicine·Deepak L BhattUNKNOWN SOLOIST-WHF Trial Investigators
Dec 1, 2020·European Journal of Heart Failure·Milton PackerUNKNOWN EMPEROR Trial Committees and Investigators
Mar 2, 2021·Journal of Clinical Anesthesia·João Paulo Jordão PontesLaís Helena Navarro E Lima

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.